Drug Profile


Alternative Names: Aravive S-6; AVB 500; AVB S6 500; Ruga-S6

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer Aravive Biologics
  • Class Immunoglobulin Fc fragments; Proteins; Recombinant fusion proteins
  • Mechanism of Action Axl receptor tyrosine kinase modulators; Growth arrest-specific protein 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Solid tumours
  • Discontinued Viral infections

Most Recent Events

  • 16 Aug 2018 Aravive Biologics and Washington University School of Medicine plans a phase I trial in Ovarian cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or graeter) in USA in October 2018 (IV) (NCT03607955)
  • 10 Jul 2018 Aravive Biologics plans a phase Ib portion of phase Ib/II trial (Combination therapy) in Ovarian cancer in second half of 2018
  • 10 Jul 2018 Aravive Biologics completes a phase I trial in healthy volunteers in USA (NCT03401528)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top